18F-FLT

also known as 3'deoxy-3'-(18)F-fluorothymidine · Fluorothymidine F-18 · F-18 FLT · 18Ffluoro-deoxy-L-thymidine · [F-18] Fluorothymidine · FLT

Diagnostic / imaging agent

Trials 21

today NCT07609225 · Ph 0 NCT03613259 · Ph 0 NCT03276676 · Ph 1/2 NCT03422731 · Ph 0 NCT02241668 · not/applicable NCT01717391 · Ph 2 NCT01610544 · Ph 2 NCT01480583 · Ph 2 NCT01928186 · not/applicable NCT01399658 · Ph 2 NCT01338987 · Ph 2 NCT00813566 · Ph 1 NCT01244737 · Ph 2 NCT01243619 · not/applicable NCT01713049 · not/applicable NCT00979810 · not/applicable NCT00894101 · Ph 2/3 NCT00847509 · not/applicable NCT00572728 · Ph 2 NCT00633958 · Ph 1 NCT00553748 · Ph 1

20082009201020112012201320142015201620172018201920202021202220232024202520262027202820292030

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 03 trials
Phase 0	NCT07609225	Oct 2026 → Sep 2029 expected	castration-resistant prostate carcinoma	University of Wisconsin, Madison	Not yet recruiting	No outcome recorded
Phase 0	NCT03613259	Jun 2020 → Jun 2022	soft tissue sarcoma	OHSU Knight Cancer Institute	Withdrawn	No outcome recorded Stop: Business
Phase 0	NCT03422731	Feb 2018 → Nov 2026 expected	acute lymphoblastic leukemia, acute myeloid leukemia	City of Hope Medical Center	Active not recruiting	No outcome recorded
Phase 13 trials
Phase 1	NCT00813566	Nov 2010 → Feb 2015	brain neoplasm, cancer	University of Utah	Completed	No outcome recorded
Phase 1	NCT00633958	Mar 2008 → Mar 2010	central nervous system neoplasm	Dana-Farber Cancer Institute	Terminated	No outcome recorded
Phase 1	NCT00553748	Nov 2007 → May 2008	brain cancer	Siemens Molecular Imaging	Completed	No outcome recorded
Phase 1/21 trial
Phase 1/2	NCT03276676	Sep 2018 → Apr 2021	brain neoplasm	University of Utah	Terminated	No outcome recorded Stop: Enrollment
Phase 27 trials · 2 met primary
Phase 2	NCT01717391	Oct 2012 → Feb 2016	anus neoplasm, endometrium neoplasm, prostate neoplasm, uterine cervix neoplasm	John M. Buatti	Completed	No outcome recorded
Phase 2	NCT01610544	May → Dec 2012	non-small cell lung carcinoma, thymus neoplasm	National Cancer Institute (NCI)	Withdrawn	No outcome recorded
Phase 2	NCT01480583	Oct 2011 → Jun 2015	breast cancer, metastatic malignant neoplasm in the brain	Angiochem Inc	Completed	No outcome recorded
Phase 2	NCT01399658	Sep 2011 → Feb 2016	cervical cancer, vaginal cancer, vulvar carcinoma	Dana-Farber Cancer Institute	Completed	No outcome recorded
Phase 2	NCT01338987	Apr 2011 → Dec 2017	acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia, chronic myelomonocytic leukemia +1	National Cancer Institute (NCI)	Completed	Met primary
Phase 2	NCT01244737	Oct 2010 → Feb 2023	brain neoplasm	Frederick Daniel Grant	Completed	No outcome recorded
Phase 2	NCT00572728	Dec 2008 → Sep 2014	female breast carcinoma	National Cancer Institute (NCI)	Completed	Met primary
Phase 2/31 trial
Phase 2/3	NCT00894101	May 2009 → Apr 2010	head and neck cancer	University of California, Irvine	Withdrawn	No outcome recorded
Phase not applicable6 trials
—	NCT02241668	Jun 2015	brain neoplasm	M.D. Anderson Cancer Center	Withdrawn	No outcome recorded
—	NCT01928186	Sep 2011 → Jul 2015	Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, male breast carcinoma	University of Washington	Completed	No outcome recorded
—	NCT01243619	Aug 2010 → Mar 2013	esophageal cancer	Dana-Farber Cancer Institute	Completed	No outcome recorded
—	NCT01713049	Aug 2010 → Dec 2012	breast neoplasm	National Taiwan University Hospital	Unknown	No outcome recorded
—	NCT00979810	Sep 2009 → Feb 2020	brain cancer, glioma	Memorial Sloan Kettering Cancer Center	Completed	No outcome recorded
—	NCT00847509	Feb 2009 → Aug 2010	head and neck cancer, lung cancer	Siemens Molecular Imaging	Completed	No outcome recorded

Evidence & citations 9 cited values

Every value below carries the sentence it was read from. 22 sources stand behind the page.

Field	Value	Cited text
Known as	(18)F-FLT	“Our objective was to determine whether early change in standardized uptake values (SUVs) of 3'deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) using PET with CT could predict...” PMID 26359256 ↗ Sep 2015 8 NCT00633958 ↗ NCT00979810 ↗ NCT01480583 ↗ NCT01338987 ↗ NCT03276676 ↗ NCT01713049 ↗ NCT00572728 ↗ NCT01244737 ↗
Known as	18Ffluoro-deoxy-L-thymidine	“An imaging technique using a very small amount of a radioactive tracer called 18Ffluoro-deoxy-L-thymidine (18F-FLT) can detect areas of rapid growth within the tumor.” NCT00979810 ↗
Known as	3'deoxy-3'-(18)F-fluorothymidine	“Our objective was to determine whether early change in standardized uptake values (SUVs) of 3'deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) using PET with CT could predict...” PMID 26359256 ↗ Sep 2015 6 NCT02241668 ↗ NCT07609225 ↗ NCT00813566 ↗ NCT01399658 ↗ NCT01243619 ↗ NCT01610544 ↗
Known as	[F-18] Fluorothymidine	“[F-18] Fluorothymidine” NCT01717391 ↗
Known as	F-18 FLT	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00553748 ↗ 2 NCT00847509 ↗ NCT00894101 ↗
Known as	FLT	“3'-deoxy-3'-18F fluorothymidine (FLT)” NCT01610544 ↗
Known as	Fluorothymidine F-18	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03613259 ↗ 3 NCT01928186 ↗ NCT03422731 ↗ NCT01717391 ↗
Modality	Diagnostic / imaging agent	“PET imaging tracer” NCT00553748 ↗
Route	Intravenous	“administered IV” NCT00553748 ↗